Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Intellia Therapeutics, Inc.

NASDAQ: NTLA · Life Sciences · 6 alerts · CIK 1652130

Share price
$9.86Close, Nov 16
Market cap
$1.38B
Shares outstanding
140.36MLatest SEC cover page
Sector
Life Sciences
Industry
In Vitro & In Vivo Diagnostic SubstancesSIC 2835

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Intellia Therapeutics, Inc. filings on SEC EDGAR ↗

5:06 PM ET 8-K/A
Investor Presentation

Intellia Therapeutics Investor Presentation

Intellia Therapeutics hosted a webcast and filed a formal investor presentation titled 'Readying Lonvo-z for Patients with HAE.' The presentation focused on the commercial potential and clinical data for lonvoguran ziclumeran (lonvo-z), a CRISPR-based therapy for hereditary angioedema.

4:15 PM ET 8-K
Investor Presentation

Intellia Therapeutics Investor Presentation

Intellia Therapeutics hosted a webcast for investors and analysts titled 'Readying Lonvo-z for Patients with HAE' to discuss the development and commercialization strategy for its CRISPR-based therapy, lonvoguran ziclumeran. The presentation focused on the clinical data and market potential for lonvo-z in treating hereditary angioedema (HAE).

4:18 PM ET 10-Q
Financial Results

Intellia Therapeutics Q3 2026 Results: Net Loss of $127M, Loss Widens

Intellia Therapeutics reported a net loss of $127.5 million for the third quarter of 2026, driven by a decrease in collaboration revenue and increased general and administrative expenses. The company strengthened its balance sheet during the nine months ended September 30, 2026, through a follow-on public offering and new debt issuance, resulting in total cash, cash equivalents, and marketable securities of approximately $614.8 million.

Key figure
Net loss $127M
8:16 AM ET 8-K
Financial Results

Intellia Therapeutics Financial Results

Intellia Therapeutics reported Q3 2026 financial results, highlighting the FDA's acceptance and Priority Review of the BLA for lonvo-z with a PDUFA date of March 10, 2027. The company completed enrollment in its MAGNITUDE-2 Phase 3 trial for ATTRv-PN and expects its current cash position to fund operations into 2028.

Counterparty
Regeneron Pharmaceuticals, Inc.
Term
Q3 2026

“This is a defining period for Intellia as we advance our late-stage pipeline and prepare for a transformative year ahead. We have assembled the teams and capabilities needed to support a successful launch in HAE while also continuing to advance nex-z’s Phase 3 clinical trials and our pipeline expansion efforts. Looking to 2027, we are working toward a historic milestone: the potential approval of lonvo-z as the world’s first in vivo CRISPR-based therapy.”

John Leonard, M.D., Intellia President and Chief Executive Officer
4:21 PM ET Form 4
Insider Selling

Intellia Therapeutics President and CEO John M. Leonard Sells $108K of Stock

John M. Leonard, President and CEO, sold 9,000 shares of Intellia Therapeutics, Inc. at $11.99 a share, worth $108K in total on Nov 2, 2026. Shares held after the trade: 1,138,064 (-0.8%).

Value
$108K
Shares
9,000
Price
$11.99
Role
President and CEO
Holding change
-0.8%
Trade date
Nov 2, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.